[Results of a multicenter, phase-II clinical trial of Dicarbamin used to shield leukopoiesis in cancer patients with immunosuppression due to chemotherapy].
Garin
A M
AM
Gorbunova
V A
VA
Bychkov
M B
MB
Mindra
N V
NV
Stenina
M B
MB
Topchieva
S V
SV
Treshchalina
E M
EM
Chitiia
L V
LV
Sdvizhkov
A M
AM
Borisov
V I
VI
Gurov
S N
SN
Gershanovich
M L
ML
Makhnova
E V
EV
Nebol'sin
V E
VE
D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects*; D002208:Caproates; D005260:Female; D006801:Humans; D007093:Imidazoles / Q000494:pharmacology / Q000627:therapeutic use*; D007165:Immunosuppression Therapy; D007970:Leukopenia / Q000139:chemically induced / Q000517:prevention & control; D019891:Leukopoiesis / Q000187:drug effects*; D008297:Male; D008875:Middle Aged; D009503:Neutropenia / Q000139:chemically induced / Q000517:prevention & control; D013921:Thrombocytopenia / Q000139:chemically induced / Q000517:prevention & control; D016896:Treatment Outcome
D000970:Antineoplastic Agents; D002208:Caproates; D007093:Imidazoles; C539419:pentanedioic acid imidazolyl ethanamide